Scarica l'app Stockscreener
88.17
3.36%
2.87
Pre-mercato:
88.19
0.02
+0.02%
Precedente Chiudi:
$85.30
Aprire:
$86.06
Volume 24 ore:
1.81M
Relative Volume:
1.59
Capitalizzazione di mercato:
$10.99B
Reddito:
-
Utile/perdita netta:
$-507.65M
Rapporto P/E:
-19.17
EPS:
-4.6
Flusso di cassa netto:
$-616.24M
1 W Prestazione:
+12.84%
1M Prestazione:
+1.90%
6M Prestazione:
+8.01%
1 anno Prestazione:
+45.57%
Intervallo 1D:
$85.24
$88.54
Intervallo di 1 settimana:
$80.30
$90.06
Portata 52W:
$58.10
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
Nome
Vaxcyte Inc
Settore
Industria
Telefono
650-837-0111
Indirizzo
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Confronta PCVX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
88.17 | 10.99B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Iniziato | Goldman | Buy |
| 2023-12-07 | Iniziato | Mizuho | Buy |
| 2023-04-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-03 | Reiterato | Needham | Buy |
| 2022-12-15 | Iniziato | Guggenheim | Buy |
| 2022-11-17 | Iniziato | BTIG Research | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-24 | Ripresa | Jefferies | Buy |
| 2020-07-07 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Iniziato | Needham | Buy |
Mostra tutto
Vaxcyte Inc Borsa (PCVX) Ultime notizie
CARGO Therapeutics, Inc. Enters into Sublease Agreement with Vaxcyte, Inc -July 08, 2024 at 04:18 pm EDT - Marketscreener.com
Vaxcyte Catapults As It Looks To Take On Pfizer, Merck In A Massive Market - MSN
Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts? - Insider Monkey
Vaxcyte (NASDAQ:PCVX) Trading Up 7.8%Should You Buy? - MarketBeat
Teri Loxam Sells 6,250 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock - MarketBeat
Alexandria Announces Long-Term Lease at San Carlos Mega Campus - MSN
Learn to Evaluate (PCVX) using the Charts - Stock Traders Daily
Vaxcyte (NASDAQ:PCVX) Stock Price Up 7.8%Here's What Happened - MarketBeat
Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy (NASDAQ:PCVX) - Seeking Alpha
Leerink Partnrs Forecasts Vaxcyte FY2029 Earnings - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Harbor Capital Advisors Inc. - MarketBeat
Diversified Trust Co Acquires New Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte's SVP Mikhail Eydelman sells $427,922 in stock - Investing.com India
Vaxcyte's SVP Mikhail Eydelman sells $427,922 in stock By Investing.com - Investing.com Canada
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm - The Malaysian Reserve
Long Term Trading Analysis for (PCVX) - Stock Traders Daily
Brokerages Set Vaxcyte, Inc. (NASDAQ:PCVX) Target Price at $145.71 - MarketBeat
Vaxcyte COO Jim Wassil sells shares valued at $669,266 By Investing.com - Investing.com Australia
Jim Wassil Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock - MarketBeat
Vaxcyte COO Jim Wassil sells shares valued at $669,266 - Investing.com
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Principal Financial Group Inc. - MarketBeat
Trump and Interest Rates: The 2 Key Reasons This Vanguard ETF Could Thrive in 2025 - The Motley Fool
Vaxcyte (NASDAQ:PCVX) Trading Down 5.8%Here's What Happened - MarketBeat
When (PCVX) Moves Investors should Listen - Stock Traders Daily
Is Vaxcyte, Inc. (PCVX) the Best Performing Biotech Stock in 2024? - MSN
10 Best Performing Biotech Stocks in 2024 - Insider Monkey
Vaxcyte stock supported by Goldman Sachs for addressing next-gen vaccine challenges - Investing.com Canada
Vaxcyte a new buy at Goldman Sachs on vaccine platform, pneumonia asset - MSN
Vaxcyte a new buy at Goldman Sachs on vaccine platform, pneumonia asset (PCVX:NASDAQ) - Seeking Alpha
Vaxcyte (NASDAQ:PCVX) Coverage Initiated at The Goldman Sachs Group - MarketBeat
Vaxcyte's president and CFO sells $710,248 in stock transactions - Investing.com India
Vaxcyte's president and CFO sells $710,248 in stock transactions By Investing.com - Investing.com Canada
Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells 8,000 Shares of Stock - MarketBeat
Vaxcyte’s president and CFO sells $710,248 in stock transactions By Investing.com - Investing.com Nigeria
(PCVX) Investment Report - Stock Traders Daily
Lord Abbett & CO. LLC Raises Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Franklin Resources Inc. Raises Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Geode Capital Management LLC Buys 259,010 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Receives $147.50 Average Price Target from Analysts - MarketBeat
Applied Industrial Technologies (AIT-N) QuotePress Release - The Globe and Mail
Merck & Company (MRK-N) QuotePress Release - The Globe and Mail
Why Wall Street Rates These 2 Russell 2000 Stocks a “Strong Buy” - MSN
Pfizer Inc (PFE-N) QuotePress Release - The Globe and Mail
Vaxcyte Inc Azioni (PCVX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):